 So an endpoint in the clinical trial is the way to tell if the trial is successful or not The main endpoint which we're using is survival because if the patient is live or die That is the most important point in doing the trial. However now in myeloma that we have very good treatments We need to clarify And wait a lot of years In order to see if the patient is dead or alive So we need other endpoints to tell us to foretell if they are in correlation to this survival endpoint so we have response response if the patient is in good response or in Very good response or in an excellent response that would correlate also with this endpoint of overall survival if the disease returns Which is progression free survival. Usually it also will correlate with overall survival of the patients and as we the treatments are much better Then we get very good responses and very deep responses. So we can now measure If there is a remnant of myeloma It's in the bone marrow to see one cell out of a million And if the patients don't have even this one cell, maybe we're close to cure. Maybe this will Be correlating with a very prolonged overall survival of the patients So we can get in the clinical trial that most patients have achieved this Minimal residual disease and this will also correlate with them surviving for a longer time So a biomarker is is um clinical Lab test Whatever it is that will help us In a surrogate way if you'd like to to Say it to assess this response. So if it's the free light chain or if it's the The para protein the immunofixation The bone marrow with the mrd testing as we were saying these are all biomarkers that help us to assess the situation of the patient even the prognostic Markers when we we do the first bone marrow with the with the cytogenetics With the amount of plasma cells with the beta 2 microglobulin levels and the Albumin levels. These are all biomarkers that help us assess At the current point of time. What's going to happen with the patient a long time? So that's the basic idea. We can measure now minimal residual disease by various methods We have the method of using a flow cytometry. This sees Every cell and differentiates every cell from the other so we can differentiate not only the plasma cells from Other cells in the bone marrow. We can differentiate the sick plasma cells from all plasma cells And therefore if we don't see them that means that there are no more sick cells within the marrow another method is to do it by what's called Next generation sequencing we can find a signature of the sick plasma cell and We can amplify it So if there are many cells we will amplify it and see them But if there are hardly any cells we can try to amplify it and we won't see them That is also meaning that there are very few cells within the bone marrow sick cells And that is also correlating with minimal residual disease being negative So At the current point of time. We don't know. We don't know if it's actually The nature of the disease And response to treatment. So the the patient has good prognosis and therefore he has a negative mrd or Should we aim for this mrd by adding more treatment but in the future of clinical trials are trying to answer this question